Death and Dying in Hospitalized Pediatric Patients: A Prospective Multicenter, Multinational Study

Jessica Nicoll1,2,3,4, Karen Dryden-Palmer1, Helena Frndova1

  • 1Department of Critical Care Medicine, Hospital for Sick Children, Toronto, Ontario, Canada.

Insights

Most pediatric inpatient deaths occur in the pediatric intensive care unit (PICU), where children are less likely to have end-of-life care plans like a "do-not-resuscitate" (DNR) order or palliative care consult. Integrating palliative care may improve end-of-life care for these children.

Area of Science:

  • Pediatric critical care medicine
  • Palliative care
  • End-of-life care research

Background:

  • Limited data exists on the location, mode of death, "do-not-resuscitate" (DNR) order use, and palliative care team involvement for hospitalized children outside of critical care units in high-income countries.
  • Understanding these factors is crucial for improving end-of-life care in pediatric hospital settings.

Purpose of the Study:

  • To describe the location of death and characteristics of patient terminal care plans for pediatric inpatient deaths occurring both inside and outside the pediatric intensive care unit (PICU).
  • To examine the association between palliative care consultation and the location of death in hospitalized children.

Main Methods:

  • Secondary analysis of data from the Evaluating Processes of Care and Outcomes of Children in Hospital (EPOCH) randomized controlled trial, involving 21 centers across multiple high-income countries.
  • Descriptive statistics were used to compare patient and terminal care plan characteristics. A multivariable generalized estimating equation model assessed the association between palliative care consult and location of death.

Main Results:

  • Of 365 pediatric inpatient deaths, 60% occurred in the PICU and 40% on other inpatient units.
  • Patients who died in the PICU were less likely to have an expected death, a DNR order, or a palliative care consult compared to those who died on other wards.
  • Hospital palliative care consultation was associated with a lower adjusted odds of dying in the PICU and was more common in older children.

Conclusions:

  • The majority of pediatric inpatient deaths occur in the PICU, often without documented end-of-life care plans such as DNR orders or palliative care consults.
  • Palliative care consultation is independently associated with a lower likelihood of dying in the PICU.
  • There is a need to better integrate palliative care consultation into end-of-life care for children, particularly younger children and those dying within the PICU.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
20
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
19
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
18
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
68
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
33
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
27